FDA, EU agree to review Biogen's MS drug Plegridy

07/22/2013 | Pharmaceutical Business Review Online · PMLive.com (U.K.)

The FDA and the European Medicines Agency have accepted Biogen Idec's marketing applications for Plegridy, or peginterferon beta-1a, a subcutaneous injectable formulation for the treatment of relapsing forms of multiple sclerosis. The applications included data from the late-stage ADVANCE trial.

View Full Article in:

Pharmaceutical Business Review Online · PMLive.com (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN